PULMONX CORPORATION Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
PULMONX CORPORATION (LUNG) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $8.29 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-03-10
- PULMONX CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $8.29, a 8.60% decline year-over-year.
- PULMONX CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $9.07, a 20.99% decline year-over-year.
- PULMONX CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $11.48, a 56.78% decline year-over-year.
- PULMONX CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $26.56, a 57.39% decline year-over-year.
- PULMONX CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $8.29, a 7.89% decline from fiscal 2024.
- PULMONX CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $9.00, a 21.60% decline from fiscal 2023.
- PULMONX CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $11.48, a 52.35% decline from fiscal 2022.
- PULMONX CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $24.09, a 44.99% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-12-31 | $8.29 10-K · filed 2026-03-10 | |||
| 2025-09-30 | $8.29 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $8.29 10-Q · filed 2025-08-01 | |||
| 2025-03-31 | $8.29 10-Q · filed 2025-05-02 | |||
| 2024-12-31 | $9.00 10-K · filed 2026-03-10 | |||
| 2024-09-30 | $9.09 10-Q · filed 2024-11-01 | |||
| 2024-06-30 | $9.09 10-Q · filed 2024-08-02 | |||
| 2024-03-31 | $9.07 10-Q · filed 2024-05-03 | |||
| 2023-12-31 | $11.48 10-K · filed 2025-02-25 | |||
| 2023-09-30 | $11.48 10-Q · filed 2023-11-03 | |||
| 2023-06-30 | $11.48 10-Q · filed 2023-08-04 | |||
| 2023-03-31 | $11.48 10-Q · filed 2023-05-08 | |||
| 2022-12-31 | $24.09 10-K · filed 2024-02-27 | |||
| 2022-09-30 | $26.21 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $26.56 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | $26.56 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $43.79 10-K · filed 2023-03-01 | |||
| 2021-09-30 | $43.79 10-Q · filed 2021-11-09 | |||
| 2021-06-30 | $43.79 10-Q · filed 2021-08-10 | |||
| 2021-03-31 | $62.34 10-Q · filed 2021-05-12 | |||
| 2020-12-31 | $7.73 10-K · filed 2022-03-01 | |||
| 2020-09-30 | $6.36 10-Q · filed 2020-11-13 | |||
| 2019-12-31 | $1.93 10-K · filed 2021-03-15 | |||
| 2018-12-31 | $1.37 10-K · filed 2021-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SkinHealth Systems Inc. (SKIN) | United States | $0.086B | -3.17 |
| LENSAR, Inc. (LNSR) | United States | $0.087B | 2.02 |
| RenovoRx, Inc. (RNXT) | United States | $0.076B | -3.62 |
| Microbot Medical Inc. (MBOT) | $0.089B | -7.97 | |
| FRACTYL HEALTH, INC. (GUTS) | United States | $0.075B | -1.18 |
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 | |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| Spectral AI, Inc. (MDAI) | United States | $0.052B |